Aldeyra The (ALDX) Stock Analysis & Investment Frameworks
Aldeyra The (ALDX) stock analysis on Invetso. Review Aldeyra The’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aldeyra The Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Aldeyra The Key Financial Metrics
- Market Cap: $37.16M
- Revenue: $N/A
- ROE: -42.73%
- ROIC: -11.59%
- Dividend Yield: N/A
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Aldeyra The Investment Frameworks
Invetso analyzes Aldeyra The (ALDX) across the following frameworks:
- Aldeyra The 10Y Growth Potential
- Aldeyra The Scenario Analysis
- Aldeyra The Risks & Opportunities
- Aldeyra The Economic Moat
- Aldeyra The Business Model
- Aldeyra The Management
- Aldeyra The SWOT Analysis
- Aldeyra The Porter's 5 Forces
- Aldeyra The PESTLE Analysis
- Aldeyra The ESG Analysis